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Is industrial fructose just a marker of an
unhealthy dietary pattern?
To the Editor:
Letters to the EditorWe read with interest the cross-sectional study by Petta et al. [1]
showing that ‘‘industrial’’ fructose and not fruit fructose intake is
associated with liver ﬁbrosis in biopsy-proven genotype 1
chronic hepatitis C (G1CHC) patients. We are concerned that
important confounders were not included in their analytical
models.
The authors selected their multivariate models based on the
signiﬁcance of variables in univariate models. Taking this
approach, important confounders may have been missed. One
of the most important confounders in nutrition is that of energy,
a factor intrinsic to all foods. Although neither ‘‘hypercaloric’’ nor
‘‘energy intake’’ were signiﬁcant in univariate models, both were
signiﬁcantly associated with fructose intake. Excess energy has
also been shown to be an important mediating factor in the
effects of fructose on cardiometabolic risk. In a series of system-
atic reviews and meta-analyses of controlled feeding trials, we
found that fructose in isocaloric exchange for other carbohy-
drates (energy matched conditions) showed no signal for harm
in relation to markers of non-alcoholic fatty liver disease (NAFLD)
[2] as well as body weight [3], glycemic control [4], insulin [4],
serum fasting lipids [5], postprandial triglycerides [6], blood pres-
sure [7], and uric acid [8]. A lack of harm is seen even under con-
ditions of fructose overfeeding (positive energy balance) at high
doses, as long as the comparison with the carbohydrate compar-
ator remains matched for the excess calories. There may, how-
ever, be a dose threshold for some fasting lipid effects in some
high dose subgroup analyses [5]. A consistent signal for harm is
not seen until one examines fructose in imbalanced, hypercaloric
comparisons. If fructose supplements background diets with
excess energy compared with the same diets without the excess
energy, then one sees adverse effects on markers of NAFLD and
other cardiometabolic risk factors [2–8]. In the absence of a clear
effect on markers of NAFLD and its related cardiometabolic risk
factors in isocaloric comparisons (especially under conditions of
positive energy balance), the effects seen in the hypercaloric
comparisons appear to relate more to the excess energy than
the fructose. Adjustment for total energy intake would therefore
seem essential in understanding whether an association with
fructose exists beyond the energy it contributes.
Other lifestyle factors associated with NAFLD were also not
adjusted for in their multivariate models. These include smoking,
exercise, total fat, trans fat, saturated fat, cholesterol, the n-6:-3
ratio of polyunsaturated fatty acids, total carbohydrate, animal
protein, dietary ﬁbre, and an overall Western dietary pattern
which embodies these variables. Even if some of these factors
were not signiﬁcant in univariate analyses, each has been shown
to have an equal or stronger association with NAFLD [9,10] and
may contribute to residual confounding. These factors individu-
ally and collectively may also contribute to important collinearity
effects, as high consumers of added sugars (in the form of sugar
sweetened beverages) tend to smoke more, exercise less, and
eat more calories in the form of a Western dietary pattern char-
acterized by increased red meat, processed meat, potato prod-
ucts, and reﬁned grains. The lack of adjustment for these
factors greatly complicates the interpretation of the results.172 Journal of Hepatology 20
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NAFLD, one cannot conclude with conﬁdence that ‘‘industrial’’
fructose is a risk factor for liver ﬁbrosis in biopsy-proven
G1CHC patients. Added fructose from industrial sources may sim-
ply represent a marker of an unhealthy lifestyle pattern in these
patients. To understand whether fructose is an independent pre-
dictor of liver ﬁbrosis, the authors must address these confound-
ers in future models. There also remains an urgent need for
higher quality evidence from well-conducted prospective obser-
vational studies with good measurements of exposure and the
ability to adjust for known confounders as well as longer, larger,
higher quality randomized controlled trials of the effect of
fructose on the progression of NAFLD.
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Reply to: ‘‘Is industrial fructose just a marker
of an unhealthy dietary pattern?’’
To the Editor:
We recently reported a link between fructose intake and the
severity of liver ﬁbrosis in a cohort of Italian patients with
genotype 1 (G1) chronic hepatitis C (CHC) [1]. In particular, the
association holds true for ‘‘industrial’’ only, not for ‘‘fruit’’
fructose intake.
We thank Chiavaroli and colleagues for their comments that
give us the opportunity to further strengthen data from our
analyses.
Firstly, they question the approach we used for the multivar-
iate model assessing variables independently associated with
severe liver ﬁbrosis. Speciﬁcally, they raised concerns about the
lack of adjustment for energy intake, a variable associated in
our analysis with industrial fructose intake, not with liver ﬁbro-
sis. From a methodological point of view the choice of indepen-
dent variables included in the ﬁnal multivariate analysis is not
a simple task, particularly in relatively small databases. To
enhance the accuracy of the model, the number of independent
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